Revance to Participate in the Credit Suisse 28th Annual Healthcare Conference

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Credit Suisse 28th Annual Healthcare Conference, in Scottsdale, AZ.

Chief Financial Officer, Toby Schilke, is scheduled to present on Wednesday, November 13 at 10:20 a.m. MT.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.

About Revance Therapeutics, Inc.

Revance Therapeutics is a Silicon Valley-based biotechnology company, pioneering new innovations in neuromodulators for aesthetic and therapeutic indications. Revance’s lead product candidate, DaxibotulinumtoxinA for Injection (DAXI), combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DAXI in glabellar (frown) lines, delivering unprecedented efficacy and long-lasting duration of effect, and is pursuing U.S. regulatory approval in 2020. Revance is also evaluating DAXI in forehead lines and lateral canthal lines (crow’s feet), as well as in three therapeutic indications - cervical dystonia, adult upper limb spasticity and plantar fasciitis, with plans to study migraine. Beyond DAXI, Revance has begun development of a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences. For more information or to join our team, visit us at www.revance.com.

“Revance Therapeutics” and the Revance logo are registered trademarks of Revance Therapeutics, Inc. BOTOX® is a registered trademark of Allergan, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191106005794/en/

INVESTORS Revance Therapeutics, Inc.: Jeanie Herbert, 714-325-3584 [e-mail] or Gilmartin Group, LLC.: Laurence Watts, 619-916-7620 [e-mail]

MEDIA Revance Therapeutics, Inc.: Sara Fahy, 949-887-4476 [e-mail] or General Media: Y&R: Jenifer Slaw, 347-971-0906 [e-mail] or Trade Media: Nadine Tosk, 504-453-8344 [e-mail]